Anti-CD20 antibody treatment in refractory Class IV lupus nephritis.
Carroll
Robert P
RP
Brown
Fiona
F
Kerr
Peter G
PG
D000328:Adult; D000906:Antibodies / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000737:chemistry* / Q000276:immunology*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001379:Azathioprine / Q000494:pharmacology; D003520:Cyclophosphamide / Q000494:pharmacology; D016572:Cyclosporine / Q000494:pharmacology; D005260:Female; D006801:Humans; D008181:Lupus Nephritis / Q000276:immunology* / Q000378:metabolism* / Q000628:therapy*; D008297:Male; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D009393:Nephritis; D000069283:Rituximab; D016896:Treatment Outcome
D000906:Antibodies; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab; D016572:Cyclosporine; D003520:Cyclophosphamide; D009173:Mycophenolic Acid; D001379:Azathioprine